1. Home
  2. HIW vs CRNX Comparison

HIW vs CRNX Comparison

Compare HIW & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HIW

Highwoods Properties Inc.

HOLD

Current Price

$31.22

Market Cap

3.5B

Sector

Real Estate

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$84.97

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIW
CRNX
Founded
1978
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.9B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
HIW
CRNX
Price
$31.22
$84.97
Analyst Decision
Hold
Strong Buy
Analyst Count
7
8
Target Price
$27.57
$76.75
AVG Volume (30 Days)
906.2K
2.4M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
8.43%
N/A
EPS Growth
54.26
N/A
EPS
0.29
N/A
Revenue
$806,112,000.00
$1,039,000.00
Revenue This Year
$6.03
$720.10
Revenue Next Year
$3.58
$184.67
P/E Ratio
$108.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.45
$32.30
52 Week High
$35.44
$85.01

Technical Indicators

Market Signals
Indicator
HIW
CRNX
Relative Strength Index (RSI) 50.64 89.88
Support Level $31.01 $83.47
Resistance Level $32.18 N/A
Average True Range (ATR) 0.55 0.12
MACD -0.05 -0.86
Stochastic Oscillator 73.14 93.85

Price Performance

Historical Comparison
HIW
CRNX

About HIW Highwoods Properties Inc.

Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: